Iptacopan hydrochloride by Novartis for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis): Likelihood of Approval

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase II for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis).

Q&A: Microsoft research head explains how generative AI could help doctors be more human

Generative AI is having a moment. Peter Lee, who oversees Microsoft’s approach to health care and co-authored the 2023 book “The AI Revolution in Medicine:

March 5, 2024

Cannabis Use in Teens, Young Adults Linked to Lower Academic Success

Cannabis use during adolescence and young adulthood was linked to lower academic performance, a systematic review and meta-analysis suggested. Among 63 studies that comprised 438,329

October 8, 2024

AbbVie seeks Restasis follow-up with small option fee for Aldeyra’s eye drops, despite a potential ‘imminent’ CRL

As AbbVie’s sales of its dry eye disease drug Restasis continue to slide following the first generic approval in February 2022, the Big Pharma is

November 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.